A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Primary Outcome Measures

1. Relative change in body weight
   Measured as percentage (%).

Secondary Outcome Measures

1. Relative change in body weight
   Measured as %.
2. Change in Body Mass Index (BMI)
   Measured as kilograms per square metre (kg/m\^2).
3. Number of participants who achieve greater than or equal to (≥) 30% weight reduction
   Measured as count of participants.
4. Number of participants who achieve ≥25% weight reduction
   Measured as count of participants.
5. Number of participants who achieve greater ≥ 20% weight reduction
   Measured as count of participants.
6. Change in waist circumference
   Measured in centimetre (cm).
7. Mean change in body weight
   Measured in kilograms (kg).
8. Number of participants who achieve a BMI less than (<) 30 kg/m^2
   Measured as count of participants.
9. Number of participants who achieve BMI <27 kg/m^2
   Measured as count of participants.
10. Number of participants who achieve normal BMI, defined as 18.5 lesser than or equal to (≤) BMI < 25 kg/m^2
    Measured as count of participants.
11. Number of participants who achieve a waist-to-height ratio < 0.53
    Measured as count of participants.
12. Ratio to baseline : Total cholesterol
    Measured in terms of ratio.
13. Ratio to baseline : High density lipoprotein (HDL) cholesterol
    Measured in terms of ratio.
14. Ratio to baseline : Low density lipoprotein (LDL) cholesterol
    Measured in terms of ratio.
15. Ratio to baseline : Very low density lipoprotein ( VLDL) cholesterol
    Measured in terms of ratio.
16. Ratio to baseline : Triglycerides
    Measured in terms of ratio.
17. Ratio to baseline: Free fatty acids
    Measured in terms of ratio.
18. Ratio to baseline : Non-HDL cholesterol
    Measured in terms of ratio.
19. Change in Short-Form-36 Health Survey Version 2.0 (SF-36v2) physical Function
    Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.
20. Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) physical function
    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.
21. Change in glycated haemoglobin (HbA1c)
    Measured in %-points.
22. Number of participants who achieve HbA1c <6.5%
    Measured as count of participants.
23. Number of participants who achieve normal HbA1c <5.7%
    Measured as count of participants.
24. Number of treatment-emergent adverse events (TEAEs)
    Measured in number of events.
25. Number of treatment-emergent serious adverse events (TESAEs)
    Measured in number of events.